ArticleThe CRISPR journal2019
An Engineered Cas-Transposon System for Programmable and Site-Directed DNA Transpositions.
Article in The CRISPR journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 47 citations in OpenAlex.
- Programmable enzymes for targeted gene insertion.Nature reviews. Genetics · 2026Review
- CRISPR-AuNP: physicochemical optimization of a gold nanoparticle platform for cost-effective and modular non-viral gene editing in HSPCs.Gene therapy · 2026Article
- Precision gene editing: The power of CRISPR-Cas in modern genetics.Molecular therapy. Nucleic acids · 2025Review
- Programmable gene insertion in human cells with a laboratory-evolved CRISPR-associated transposase.Science (New York, N.Y.) · 2025Article
- Next-generation probiotics and engineered BEVs for precision therapeutics in osteoporosis.Frontiers in nutrition · 2025Review
- From bench to bedside: cutting-edge applications of base editing and prime editing in precision medicine.Journal of translational medicine · 2024Review
- Natural and Engineered Guide RNA-Directed Transposition with CRISPR-Associated Tn7-Like Transposons.Annual review of biochemistry · 2024Review
- Cas9 RNP Physiochemical Analysis for Enhanced CRISPR-AuNP Assembly and Function.bioRxiv : the preprint server for biology · 2024Article
- Recent advances in CRISPR-Cas9-based genome insertion technologies.Molecular therapy. Nucleic acids · 2024Review
- Targeted DNA integration in human cells without double-strand breaks using CRISPR-associated transposases.Nature biotechnology · 2024Article
- Drag-and-drop genome insertion of large sequences without double-strand DNA cleavage using CRISPR-directed integrases.Nature biotechnology · 2023Article
- Targeted DNA integration in human cells without double-strand breaks using CRISPR RNA-guided transposases.bioRxiv : the preprint server for biology · 2023Article
- Computational Tools and Resources for CRISPR/Cas Genome Editing.Genomics, proteomics & bioinformatics · 2023Review
- A Framework for the Systematic Selection of Biosensor Chassis for Environmental Synthetic Biology.ACS synthetic biology · 2022Review
- Activating natural product synthesis using CRISPR interference and activation systems in Streptomyces.Nucleic acids research · 2022Article
- CRISPR-based genome editing through the lens of DNA repair.Molecular cell · 2022Review
- Genetically engineered bacterium: Principles, practices, and prospects.Frontiers in microbiology · 2022Review
- CRISPR RNA-guided integrases for high-efficiency, multiplexed bacterial genome engineering.Nature biotechnology · 2021Article
- Prime Editing Guide RNA Design Automation Using PINE-CONE.ACS synthetic biology · 2021Article
- Advances and Obstacles in Homology-Mediated Gene Editing of Hematopoietic Stem Cells.Journal of clinical medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Efficient site-directed insertion of heterologous DNA into a genome remains an outstanding challenge. Recombinases that can integrate kilobase-sized DNA constructs are difficult to reprogram to user-defined loci, while genomic insertion using CRISPR-Cas methods relies on inefficient host DNA repair machinery. Here, we describe a Cas-Transposon (CasTn) system for genomic insertions that uses a Himar1 transposase fused to a catalytically dead dCas9 nuclease to mediate programmable, site-directed transposition. Using cell-free
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.